LLY

991.54

+0.35%↑

JNJ

224.8

+1.37%↑

ABBV

207.81

+2%↑

UNH

386.61

+1.48%↑

AZN

184.22

-0.29%↓

LLY

991.54

+0.35%↑

JNJ

224.8

+1.37%↑

ABBV

207.81

+2%↑

UNH

386.61

+1.48%↑

AZN

184.22

-0.29%↓

LLY

991.54

+0.35%↑

JNJ

224.8

+1.37%↑

ABBV

207.81

+2%↑

UNH

386.61

+1.48%↑

AZN

184.22

-0.29%↓

LLY

991.54

+0.35%↑

JNJ

224.8

+1.37%↑

ABBV

207.81

+2%↑

UNH

386.61

+1.48%↑

AZN

184.22

-0.29%↓

LLY

991.54

+0.35%↑

JNJ

224.8

+1.37%↑

ABBV

207.81

+2%↑

UNH

386.61

+1.48%↑

AZN

184.22

-0.29%↓

Home・Lista de Ações・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Abrir

SetorSaúde

12.57 -2.78

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

12.37

Máximo

12.88

Indicadores-chave
By Trading Economics
Rendimento	227M
Vendas	139M
P/E Médio do Setor	4.989 49.8
Margem de lucro	163.843
Funcionários	1,796
EBITDA	1.3M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+55.4% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.3B
Abertura anterior	15.35
Fecho anterior	12.57

Sentimento de Notícias

By Acuity

50%

175 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

14.24 / 14.78 Suporte e Resistência

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de mai. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 de mai. de 2026, 23:46 UTC

Conversa de Mercado

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 de mai. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 de mai. de 2026, 23:33 UTC

Conversa de Mercado

Gold Rises on Possible Position Adjustments -- Market Talk

11 de mai. de 2026, 22:37 UTC

Conversa de Mercado

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 de mai. de 2026, 22:32 UTC

Ganhos

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 de mai. de 2026, 22:02 UTC

Conversa de Mercado

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 de mai. de 2026, 21:49 UTC

Ganhos

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 de mai. de 2026, 21:42 UTC

Conversa de Mercado

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 de mai. de 2026, 21:31 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 de mai. de 2026, 21:23 UTC

Aquisições, Fusões, Aquisições de Empresas

CSG Systems Sale to NEC Gets CFIUS Clearance

11 de mai. de 2026, 21:12 UTC

Ganhos

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 de mai. de 2026, 21:12 UTC

Ganhos

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

11 de mai. de 2026, 20:44 UTC

Ganhos

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 de mai. de 2026, 20:43 UTC

Ganhos

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 de mai. de 2026, 20:32 UTC

Ganhos

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 de mai. de 2026, 20:32 UTC

Ganhos

CleanSpark 2Q Rev $136.4M >CLSK

11 de mai. de 2026, 20:30 UTC

Ganhos

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris 4Q Cont Ops EPS $2.24 >STE

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris 4Q Rev $1.6B >STE

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris 4Q Adj EPS $2.83 >STE

11 de mai. de 2026, 20:22 UTC

Ações em Alta

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 de mai. de 2026, 19:37 UTC

Ganhos

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 de mai. de 2026, 19:32 UTC

Conversa de Mercado

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

55.4% parte superior

Previsão para 12 meses

Média 20 USD 55.4%

Máximo 20 USD

Mínimo 20 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

14.24 / 14.78Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimento

By Acuity

175 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.